Pharmaceuticals News and Research

RSS

AJHP examines pharmacists' prescribing medications in current issue

Pharmacists' prescribing medications is a topic often discussed when health policy experts explore how to improve patient safety, medication-use outcomes, and access to medical services.

26 Dec 2011

Wolters Kluwer sells pharma-related business to Springer Science+Business Media

Wolters Kluwer, a market-leading global information services company focused on professionals, today announced that it has completed the sale of its pharma-related Marketing & Publishing Services business to Springer Science+Business Media.

26 Dec 2011

Acceleron Pharma raises $30 million through private financing

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.

23 Dec 2011

Lexicon completes rights offering

Lexicon Pharmaceuticals, Inc. announced today that it has completed its previously announced rights offering pursuant to an effective shelf registration statement.

23 Dec 2011

Veloxis, Athena partner to establish competitive presence for AtorFen in emerging markets

Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).

23 Dec 2011

Anti-cancer drugs may also fight antibiotic resistance

Drugs used to overcome cancer may also combat antibiotic resistance, finds a new study led by Gerry Wright, scientific director of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University.

23 Dec 2011

UCF scientists pioneer new source of stem cell generation

A process that prompts a single gene to generate millions of supercharged stem cells, which can then turn into any kind of cell a body needs to repair itself, has been patented at the University of Central Florida.

23 Dec 2011

Walgreen expecting sharp drop in prescription business

A contract dispute with pharmacy benefit manager Express Scripts is likely to cut the number of drugs Walgreen will sell.

23 Dec 2011

Top-line results from Noven's LDMP Phase 3 clinical study on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced top-line results from the first of two planned Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP, formerly referred to as Mesafem) for the treatment of vasomotor symptoms (VMS) associated with menopause.

23 Dec 2011

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

Momenta, Baxter partner to develop and commercialize biosimilars

Baxter International Inc. and Momenta Pharmaceuticals, Inc. today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars.

From Baxter International Inc. 23 Dec 2011

Enrollment complete in two Anacor's tavaborole Phase 3 trials on onychomycosis

Anacor Pharmaceuticals announced today that it has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole, a topical anti-fungal product candidate for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

23 Dec 2011

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Akorn, Inc., a niche generic pharmaceutical company, today announced that its wholly-owned subsidiary, Oak Pharmaceuticals, has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck A/S.

23 Dec 2011

ECMC network receives £35M grants for cancer medicine research

The Experimental Cancer Medicine Centres (ECMC) network, which runs UK clinical studies of the newest cancer treatments, has been awarded a second wave of £35M funding for the next five years.

23 Dec 2011

ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.

23 Dec 2011

New way to awaken paternal Ube3a allele linked with Angelman syndrome

Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism.

22 Dec 2011

Large-intestine bacteria may help prevent obesity

Bacteria living in people's large intestine may slow down the activity of the "good" kind of fat tissue, a special fat that quickly burns calories and may help prevent obesity, scientists are reporting in a new study.

22 Dec 2011

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.

22 Dec 2011

Drugmaker Merck to pay $24M to settle Medicaid case

Drugmaker Merck & Co. will pay Massachusetts $24 million to settle a civil lawsuit accusing a former subsidiary of causing the state to overpay pharmacists for a widely used asthma medication. Attorney General Martha Coakley said Tuesday that the deal with Merck and 12 other drugmakers who settled previously enables the state to recover more than $47 million for its Medicaid program.

22 Dec 2011

'Global Pulse' blog examines declining TB incidence in Estonia

In this post in GlobalPost's "Global Pulse" blog, journalist John Donnelly reports on tuberculosis (TB) in Estonia and how the country has significantly reduced the proportion of multi-drug resistant tuberculosis (MDR-TB) cases since 1998. He writes, "The numbers of new TB cases in Estonia were five times that of the Nordic countries in 1998, but the numbers have tumbled since then and last year Estonia had cut that in half, to 2.5 times the number."

22 Dec 2011